

## GASTROINTESTINAL (GI)

**GI 201: Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients with Metastatic Gastroesophageal Cancer**

<https://clinicaltrials.gov/ct2/show/NCT02317991?term=GI+201&rank=1>

---

**MK3475-240-0737: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)**

<https://clinicaltrials.gov/ct2/show/NCT02702401?term=Keynote-240&rank=1>

---

**N1048: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)**

<https://clinicaltrials.gov/ct2/show/NCT01515787?term=N1048&rank=1>

---

**A021501: Preoperative Extended Chemotherapy Vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas**

<https://clinicaltrials.gov/ct2/show/NCT02839343?term=A021501&rank=1>

---

**AM0010-301 (ARTIST1): A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen**

<https://clinicaltrials.gov/ct2/show/NCT02923921?term=AM0010-301&rank=1>

---

